Laboratoires Pierre Fabre SA has acquired a biotech company founded by Versant Ventures as part of a drive to expand its pipeline in oncology. The company, Vertical Bio AG, has a monoclonal antibody poised to enter clinical development for patients with non-small cell lung cancer – specifically those with mutations or amplification of the c-MET protein.
